lazertinib,amivantamab
janssen,yuhan corp
['lazertinib', 'lung', 'amivantamab']
in data presented at the 2023 american society of clinical oncology ( ) annual meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced egfr-mutated non-small cell lung cancer. read more: 
Providing #pharmacy news, clinical insights, & CE to help pharmacists deliver drug expertise & accessible patient care. Tweet us your questions & feedback!